Skip to main content
. Author manuscript; available in PMC: 2016 May 15.
Published in final edited form as: Clin Cancer Res. 2015 May 15;21(10):2221–2226. doi: 10.1158/1078-0432.CCR-14-3154

Table 2.

A partial list of mechanisms implicated in acquired resistance to EGFR TKI

Secondary Mutations Activation of alternate pathways Other pathways
EGFR T790M (24, 25) HER2 amplification (58) Activation of PD-1 (30)
EGFR D761Y (39) MET amplification (26, 27) Epithelial to mesenchymal transition (29, 33, 59)
EGFR T854A (40) mTORC1 (60) Small Cell Transformation (61, 62)
BRAF V600E (63) AXL (64)
NRAS mutation (65) IGF1-R (66, 67)
FGFR activation (68, 69)
HHS Vulnerability Disclosure